A retrospective study assessing the effects of first-line inhibitors in patients with metastatic renal cell carcinoma not meeting trial eligibility criteria
Latest Information Update: 21 Jun 2022
At a glance
- Drugs Avelumab (Primary) ; Axitinib (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
Most Recent Events
- 21 Jun 2022 New trial record
- 16 May 2022 Results presented at the 117th Annual Meeting of the American Urological Association